Welcome to our dedicated page for Gh Research Plc news (Ticker: GHRS), a resource for investors and traders seeking the latest updates and insights on Gh Research Plc stock.
GH Research Plc (GHRS) is a clinical-stage biopharmaceutical company pioneering novel therapies for treatment-resistant depression. This page provides centralized access to all official press releases, clinical trial updates, and financial disclosures, offering stakeholders a reliable resource for tracking the company’s progress.
Investors and researchers will find timely updates on mebufotenin-based drug development, including inhalable and intravenous formulations in clinical testing. The page aggregates announcements on regulatory milestones, research partnerships, and quarterly financial results, ensuring comprehensive coverage of GH Research’s advancements in mental health therapeutics.
Bookmark this page or check back regularly to stay informed about GHRS’s innovative approaches to addressing unmet needs in depression treatment. All content is sourced directly from the company to maintain accuracy and compliance with financial reporting standards.
GH Research PLC (Nasdaq: GHRS) has announced the promotion of Dr. Velichka "Villy" Valcheva to Chief Executive Officer, succeeding co-founder PD Dr. med. Theis Terwey. Dr. Valcheva, who joined the company in August 2023 and has served as Chief Medical Officer since February 2024, brings over 20 years of pharmaceutical and biotech industry leadership experience.
The company is currently screening patients for its phase 2b trial in treatment-resistant depression, with enrollment expected to complete in September 2024. Additionally, a phase 1 healthy volunteer study using GH Research's proprietary device is actively enrolling in the UK. These developments signify the company's progress in its mission to transform the treatment of psychiatric and neurological disorders.
GH Research PLC reported financial results for Q1 2024, with cash reserves of $214.0 million expected to last until 2026. The Phase 2b trial of GH001 for treatment-resistant depression is progressing, with top-line data expected in late 2024. GH002, the intravenous product candidate, showed promising results in a Phase 1 trial. The company provided updates on IND for GH001 and financial highlights.
GH Research PLC (Nasdaq: GHRS) has reported its financial results for the year ending December 31, 2022, with a net loss of $22.5 million ($0.432 loss per share), up from a $9.2 million loss in 2021. The company's cash position decreased to $251.7 million from $276.8 million.
Significant business updates include the initiation of a Phase 2b trial for its inhalable mebufotenin product, GH001, targeting treatment-resistant depression. The company also expects to submit an IND for a new aerosol delivery device in Q3 2023 and has expanded its patent portfolio to 11 families.
GH Research PLC (Nasdaq: GHRS) announced significant advancements in its clinical trials and product development. The company received initial approvals for a Phase 2b trial of GH001 for treatment-resistant depression (TRD), set to begin in Q1 2023. A proprietary aerosol delivery device for GH001 is in progress, with an IND submission anticipated in Q3 2023. Additionally, a Phase 1 trial for GH002 has started, expected to conclude in Q4 2023. The company has filed a new patent application, expanding its portfolio to 11 families. Mebufotenin has been selected as the International Nonproprietary Name for 5-MeO-DMT.
FAQ
What is the current stock price of Gh Research Plc (GHRS)?
What is the market cap of Gh Research Plc (GHRS)?
